广州达安基因股份有限公司 第一章 总则 第一条 为维护广州达安基因股份有限公司（以下简称"公司"）及公司股东 的合法权益，明确股东会的职责权限，保证股东会依法行使职权，依据《中华人 民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下 简称《证券法》）、《上市公司股东会规则》、《深圳证券交易所上市公司自律 监管指引第 1 号——主板上市公司规范运作》、《深圳证券交易所股票上市规则》 等有关法律、法规、规章及《广州达安基因股份有限公司章程》（以下简称《公 司章程》），制定本规则。 第二条 公司应当严格按照法律、行政法规、《公司章程》及本规则的相关 规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第三条 本规则适用于公司年度股东会和临时股东会（以下统称为"股东会"）。 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的6个月内举行。临时股东会不定期召开，出现《公 司法》第一百一十三条和 ...

第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东会 第一节 股东的一般规定 第二节 控股股东和实际控制人 第三节 股东会的一般规定 第四节 股东会的召集 第五节 股东会的提案与通知 第六节 股东会的召开 第七节 股东会的表决和决议 广州达安基因股份有限公司 章 程 目录 第一章 总则 第五章 董事会 第六章 党建工作 1 第一节 董事的一般规定 第二节 董事会 第三节 独立董事 第四节 董事会专门委员会 第七章 高级管理人员 2 第八章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第九章 通知和公告 第一节 通知 第二节 公告 第十章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 第十一章 修改章程 第十二章 附则 第一章 总则 第一条 为维护广州达安基因股份有限公司(以下简称"公司"或"本公司")、 股东、职工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和 国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》（以下简称《证 ...

广州达安基因股份有限公司 （002030） 2025 年半年度报告 中国∙广东∙广州 2025 年 08 月 广州达安基因股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人韦典含、主管会计工作负责人黄志征及会计机构负责人(会计 主管人员)潘俊声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质 承诺，投资者及相关人士均应对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。 公司在本报告第三节"管理层讨论与分析"之"十、公司面临的风险和应 对措施"描述了公司经营中可能面对的风险，敬请广大投资者注意阅读。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 1 | 第一节 | 重要提示、目录和释义 | | 1 | | --- | --- | --- | --- | | 第二节 | 公司简介和主要财务 ...

Core Viewpoint - The outbreak of Chikungunya virus in Guangdong, China, has led to a rapid response from domestic diagnostic companies, but none have obtained the necessary NMPA Class III medical device registration for their nucleic acid testing kits, limiting their use to research and public health scenarios [2][3][6]. Group 1: Current Situation of Chikungunya Virus Testing - The nucleic acid testing method is preferred over antibody testing due to its higher sensitivity and specificity during the acute phase of the disease, yet all currently used products lack registration [3][6]. - Chikungunya virus is not a new disease, first identified in Tanzania in 1952, and China has had industry standards for its diagnosis since 2018, but the limited market size has deterred companies from investing in product development [3][6]. - As of 2025, there are still no registered nucleic acid testing products for Chikungunya virus in China, despite the ongoing public health needs [3][6]. Group 2: Challenges in Product Registration - The registration process for nucleic acid diagnostic kits is complex and costly, requiring clinical trials with at least 200 participants across three different medical institutions, leading to a minimum cost of over one million yuan [6][7]. - The unpredictable market size for Chikungunya virus testing further discourages companies from pursuing registration, as the registration certificate must be renewed every five years with additional research data [6][7]. Group 3: Government Procurement and Pricing - Despite the lack of registration, nucleic acid testing kits have been included in emergency government procurement, with prices as low as 1.48 yuan per person for certain suppliers [7][10]. - The Guangzhou Disease Control Center has initiated multiple rounds of emergency procurement for Chikungunya virus nucleic acid testing kits, indicating a pressing need for these products in public health responses [7][10]. Group 4: Importance of Nucleic Acid Testing - Nucleic acid testing is crucial for early detection of Chikungunya virus infections, which can lead to long-term health issues such as chronic arthritis and severe neurological diseases [17]. - Experts emphasize the need for a strategic reserve mechanism for diagnostic reagents, vaccines, and treatments to effectively manage rare but impactful infectious diseases like Chikungunya [17].

Group 1 - Multiple domestic in vitro diagnostic companies have rapidly launched virus nucleic acid test kits in response to sudden public health needs, but none have obtained Class III medical device registration from the National Medical Products Administration (NMPA) as of now, limiting their use to emergency scenarios in research or disease control [1][2][3] - The nucleic acid testing method has superior sensitivity and specificity compared to antibody methods, leading to its widespread use during the recent outbreak of Chikungunya fever, yet all currently used products lack registration [2][3] - The lack of investment in research and development for Chikungunya-related testing products is attributed to the limited market size and sporadic nature of the disease, which has hindered companies from pursuing registration [2][5] Group 2 - Despite the absence of registration, nucleic acid test kits have been included in government emergency procurement due to the sudden outbreak of Chikungunya fever [6] - The Guangzhou Disease Control Center announced an emergency procurement project for Chikungunya virus nucleic acid test kits, with a winning bid from Da An Gene at a price of 3.9 yuan per person [6] - The procurement results indicate that the price for the nucleic acid test kits is low, which may further discourage companies from pursuing product registration due to the associated costs of clinical trials and data requirements [12][13] Group 3 - The current lack of effective treatment drugs and preventive vaccines for Chikungunya fever in China emphasizes the importance of nucleic acid testing for early detection and control of the disease [16] - Experts suggest that relying solely on voluntary research and production by companies is insufficient, advocating for the establishment of a national strategic reserve mechanism for reagents, vaccines, and drugs [16]

分红多募资少。 A股市场下起"红包雨"，现金分红成为主流。 根据Wind数据，截至8月21日收盘，已有160家上市公司披露了2025年中期分红预案，仅20日晚间就有 23家公告了分红预案。其中，牧原股份（002714.SZ）的分红计划受到市场关注，该公司拟每10股派发 现金红利9.32元，分红金额超过50亿元。 此前的8月19日晚间，吉比特（603444.SH）、福耀玻璃（600660.SH）公告，每10股拟派发现金红利分 别为6.6元、0.9元，拟派发现金4.74亿元、23.49亿元。这两只股票的共同点在于，上市以来的分红总额 已超过实际募资总额。 其中，福耀玻璃是分红融资比排名前十的公司之一。依据Wind数据计算，贵州茅台（600519.SH）、山 西汾酒（600809.SH）、宁沪高速（600377.SH）、兖矿能源（600188.SH）、五粮液（000858.SZ）、 达安基因（002030.SZ）、格力电器（000651.SZ）、江铃汽车（000550.SZ）、重庆啤酒（600132.SH） 是另外9家，前十大"分红王"的分红融资比均超过24倍。其中，贵州茅台分红融资比超150倍，这意味着 每募集1 ...

Core Viewpoint - The company, Da An Gene, indicated that specific financial data should be monitored through its regular reports and related announcements [2] Summary by Relevant Categories - **Company Financials** - Da An Gene responded to investor inquiries on August 15, emphasizing the importance of following its periodic reports for detailed financial information [2]

Core Viewpoint - Da An Gene has recently obtained a medical device registration certificate from the National Medical Products Administration for its human MTHFR gene typing detection kit, which is valid until August 13, 2030 [2]. Company Summary - The newly approved kit is designed for the qualitative detection of polymorphisms at the C677T site of the MTHFR gene in human whole blood genomic DNA [2].

Group 1 - The core point of the article is that Da An Gene has received a medical device registration certificate from the National Medical Products Administration for its "Human MTHFR Gene Typing Detection Kit" [2] - In the fiscal year 2024, Da An Gene's revenue composition is projected to be 96.2% from the biopharmaceutical sector and 3.8% from financial services [2]

Core Viewpoint - DaAn Gene has recently obtained a medical device registration certificate from the National Medical Products Administration for its human MTHFR gene typing detection kit, which is designed for in vitro qualitative detection of the MTHFR gene C677T polymorphism in human whole blood genomic DNA [1] Company Summary - The medical device is named "Human MTHFR Gene Typing Detection Kit (PCR-Fluorescent Probe Method)" [1] - The kit is applicable for the qualitative detection of the MTHFR gene C677T site polymorphism [1]